CABG Medical's headway with artificial bypass graft programme
This article was originally published in Clinica
CABG Medical is pressing on with its efforts to enter the as-yet-untapped market for synthetic heart bypass grafts, after starting a 100-patient trial of its drug-eluting Holly Graft system in Australia.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.